Understanding eyebrow and eyelash involvement in patients with alopecia areata and responsiveness to treatment with baricitinib
Baseline severity of EB/EL involvement paralleled that of the scalp. Baricitinib was efficacious in achieving a holistic response across all three hair-bearing sites in the majority of week-52 scalp responders. These data detail the benefits of baricitinib across important hair-bearing sites involved in AA and highlight that individual patient treatment success should account for the totality of the clinical presentation.
Authors
- Manabu Ohyama (ORCID: https://orcid.org/0000-0002-2662-5717)
- Jerry Shapiro (ORCID: https://orcid.org/0000-0002-2971-1223)
- Justin Ko (ORCID: https://orcid.org/0000-0003-4232-5906)
- Brittany G. Craiglow (ORCID: https://orcid.org/0000-0001-8970-7691)
- Najwa Somani
- Angelina Sontag (ORCID: https://orcid.org/0000-0003-4012-4537)
- Brett King (ORCID: https://orcid.org/0000-0002-4576-4616)
- Guanglei Yu (ORCID: https://orcid.org/0000-0003-0954-3397)
- Arash Mostaghimi (ORCID: https://orcid.org/0000-0002-6084-5617)
- Antonellá Tosti (ORCID: https://orcid.org/0000-0001-5516-4043)
- Yiying Brogan
Institutions
- Fairfield University (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- University of Miami (US)
- Eli Lilly (United States) (US)
- Kyorin University (JP)
- Somerset Medical Center (US)
- Yale University (US)
- NYU Langone Health (US)
- Stanford University (US)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-04-02
- DOI
- https://doi.org/10.1093/bjd/ljaf088
- Citations
- 6
- Primary Topic
- Hair Growth and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 11.02
Funders
- American Academy of Dermatology
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Sanofi
- Regeneron Pharmaceuticals
- Incyte
- Concert Pharmaceuticals
- Horizon Therapeutics
- Sun Pharma
- LEO Pharma
- Pfizer Japan
- Sanofi Genzyme
- Janssen Pharmaceuticals